MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from sale ofproperty and equipment$55K Net cash providedby/(used) in investing...$55K Net decrease incash, cash...-$4,663K Canceled cashflow$55K Accrued expenses andother current...$2,586K Depreciation andamortization$856K Accounts payable$644K Share basedcompensation$556K Prepaid expenses andother current assets-$529K Non-cash lease expenses$210K Change in contingentconsideration$84K Non-cash interestexpense$13K Net cash used inoperating activities-$3,366K Effect of exchangerates on cash, cash...-$1,352K Canceled cashflow$5,478K Net loss-$5,534K Unrealized foreignexchange (gain)/loss$1,714K Deferred income-$1,046K Operating leaseliabilities-$347K Research and developmentincentives receivable$149K Profit on sale ofproperty and equipment$38K Deferred tax benefit-$16K
Cash Flow

Barinthus Biotherapeutics plc. (BRNS)

Barinthus Biotherapeutics plc. (BRNS)

source: myfinsight.com